title: [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
abstract: Lung cancer is the leading cause of death from cancer in the world. The treatment remains one of the most challenging tasks in the medical world. The discovery and development of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) have had a major impact in the treatment of non small cell lung cancer (NSCLC). But the efficacy of EGFR-TKI in EGFR wild-type patients is limited, and the limited EGFR mutation incidence also prompts researchers to study what is the best treatment choice for patients with NSCLC who are negative for EGFR mutations. This review will discuss the research status in treatment choice for EGFR wild-type NSCLC.
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Ma
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Shi
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Meng
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
authors.forename: Lixia
authors.initials: L
authors.lastname: Zhao
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: He
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
authors.forename: Junfeng
authors.initials: J
authors.lastname: Zhao
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors